PRRT2 and non-small cell lung carcinoma: A meta-analysis of five clinical trials for NSCLC revealed worse patient outcomes when PKC inhibitors (enzastaurin, an ATP competitive inhibitor, or aprinocarsen, a PKCα antisense oligonucleotide) were combined with chemotherapy versus chemotherapy alone [205], highlighting the complexity of protein kinase signal transduction and the need for the development of more selective tools for basic research as well as therapeutic application.